# A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

> **NCT01065454** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 202 (actual)

## Conditions studied

- Hypertension, Pulmonary
- Ventricular Dysfunction, Left

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01065454
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-14
- **Primary completion:** 2012-06-06
- **Final completion:** 2025-07-23
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065454, "A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01065454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*